Outlook Therapeutics will resubmit a biologics license application for its ophthalmic formulation of bevacizumab early next year after the second of two clinical trials missed a key target. The ...

Outlook Therapeutics (OTLK) announced preliminary topline results of Norse Eight, the second of two adequate and well controlled clinical ...

Final efficacy data expected in January 2025Anticipate resubmission of BLA in calendar Q1 2025 ISELIN, N.J., Nov. 27, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: OTLK), a biopharmaceutical company that ...

The Norse Eight trial was part of the data requested by the FDA after the agency rejected the BLA for the company’s Lytenava ...

NEW YORK, NY / ACCESSWIRE / November 27, 2024 / If you suffered a loss on your Humacyte, Inc. (NASDAQ:HUMA) investment and want to learn about a ...

U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 100 points on Wednesday. The Dow ...

U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling more than 100 points on Wednesday. The ...

At least some of the losing applicants are expected to challenge the health agency’s decisions and lead to further delays.

The selection comes more than 18 months after the application period closed in April 2023 ... OK with operating in the ...

A brawl erupted between a Thai transwoman and a foreign man at a hotel in Phuket after the foreigner refused to pay upon discovering her gender. A source, who wishes to remain anonymous, reported the ...